Sawai Group Holdings Co (4887) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
31 Jul, 2026Executive summary
Revenue for the nine months ended December 31, 2024, rose 5.3% year-over-year to JPY 143,208 million, with operating profit up 24.4% and profit attributable to owners of parent up 88.5%, driven by a gain on sale of subsidiaries and associates.
The U.S. Business was divested in April 2024, resulting in a significant gain from discontinued operations and a shift to a single-segment focus on Japan.
Growth was supported by increased sales of new and existing products, proactive lifting of shipment limitations, and effective pricing strategies.
The company is executing its medium-term plan, emphasizing growth in generics, sustainability, and capital efficiency, while responding to regulatory and market changes in Japan.
Financial highlights
Gross profit increased to JPY 45,222 million from JPY 41,873 million year-over-year, with gross profit margin improving to 31.6% from 30.8%.
Basic earnings per share for 9M FY2024 doubled to JPY 201.29 from JPY 102.75 year-over-year, reflecting both continued and discontinued operations.
Cash and cash equivalents increased by JPY 9,503 million to JPY 35,871 million as of December 31, 2024.
Free cash flow turned positive at JPY 22,682 million for 9M FY2024.
EBITDA (adjusted) for 9M FY2024 was JPY 32,816 million, up 14.0% year-over-year.
Outlook and guidance
Full-year FY2025 revenue forecast is JPY 183,900 million, with operating profit projected at JPY 23,600 million and basic EPS at JPY 212.07.
9M revenue and core operating profit are ahead of full-year forecasts, at 77.9% and 90.0% of targets, respectively.
No changes have been made to previously announced forecasts.
Latest events from Sawai Group Holdings Co
- Aims for 25%+ generics share, 25B tablet capacity, and JPY 220B–310B revenue by 2026–2030.4887
Status update31 Jul 2026 - Revenue up 6.9%, profits down on litigation; strong recovery and higher dividend forecast.4887
Q4 202531 Jul 2026 - Profit soared on U.S. business sale; growth expected from new products and production expansion.4887
Q2 202531 Jul 2026 - Operating profit soared as litigation costs fell; strong growth forecast for FY2026.4887
Q4 202631 Jul 2026 - Revenue up 12.5% YoY, profit down on settlement and U.S. exit; outlook revised upward.4887
Q2 202631 Jul 2026 - Double-digit revenue and profit growth offset by lower net profit after U.S. business exit.4887
Q1 202631 Jul 2026 - Profit surged on U.S. business sale and robust domestic operations, with focus on Japan generics.4887
Q1 202531 Jul 2026 - Revenue up 8.1% YoY, but profit down 57.8%; FY2026 outlook projects strong recovery.4887
Q3 202631 Jul 2026